Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, Loftis LL, Tarquinio KM, Singh AR, Heidemann SM, Soma VL, Riggs BJ, Fitzgerald JC, Kong M, Doymaz S, Giuliano JS, Keenaghan MA, Hume JR, Hobbs CV, Schuster JE, Clouser KN, Hall MW, Smith LS, Horwitz SM, Schwartz SP, Irby K, Bradford TT, Maddux AB, Babbitt CJ, Rowan CM, McLaughlin GE, Yager PH, Maamari M, Mack EH, Carroll CL, Montgomery VL, Halasa NB, Cvijanovich NZ, Coates BM, Rose CE, Newburger JW, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. New England Journal Of Medicine 2021, 385: 23-34. PMID: 34133855, PMCID: PMC8220972, DOI: 10.1056/nejmoa2102605.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesCombined Modality TherapyCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleGlucocorticoidsHospitalizationHumansImmunoglobulins, IntravenousImmunomodulationInfantLogistic ModelsMalePropensity ScorePublic Health SurveillanceShockSystemic Inflammatory Response SyndromeTreatment OutcomeVentricular Dysfunction, LeftYoung AdultConceptsIntravenous immune globulinMultisystem inflammatory syndromeCardiovascular dysfunctionDay 2Immunomodulatory therapyInflammatory syndromePrimary outcomeInitial treatmentLower riskRisk of feverReal-world effectivenessYears of agePropensity-score matchingImmunomodulatory medicationsVasopressor useVentricular dysfunctionAdjunctive therapyComposite outcomeImmune globulinSecondary outcomesAdjunctive treatmentRecurrent feverInverse probability weightingDay 1GlucocorticoidsIncidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2
Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, Randolph AG, Newhams M, Thomas D, Magleby R, Hsu K, Burns M, Dufort E, Maxted A, Pietrowski M, Longenberger A, Bidol S, Henderson J, Sosa L, Edmundson A, Tobin-D’Angelo M, Edison L, Heidemann S, Singh AR, Giuliano JS, Kleinman LC, Tarquinio KM, Walsh RF, Fitzgerald JC, Clouser KN, Gertz SJ, Carroll RW, Carroll CL, Hoots BE, Reed C, Dahlgren FS, Oster ME, Pierce TJ, Curns AT, Langley GE, Campbell AP, Balachandran N, Murray T, Burkholder C, Brancard T, Lifshitz J, Leach D, Charpie I, Tice C, Coffin S, Perella D, Jones K, Marohn K, Yager P, Fernandes N, Flori H, Koncicki M, Walker K, Di Pentima M, Li S, Horwitz S, Gaur S, Coffey D, Harwayne-Gidansky I, Hymes S, Thomas N, Ackerman K, Cholette J. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Network Open 2021, 4: e2116420. PMID: 34110391, PMCID: PMC8193431, DOI: 10.1001/jamanetworkopen.2021.16420.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionMultisystem inflammatory syndromeRace/ethnicityInflammatory syndromeCohort studyPacific Islander personsAge groupsCurrent SARS-CoV-2 infectionIncidence of MISPopulation-based incidenceWhite personsPopulation-based estimatesEnhanced surveillance dataSARS-CoV-2Rare complicationCOVID-19 casesLatino personsNational surveillanceMAIN OUTCOMEInfectionDisease controlIncidenceSurveillance dataCOVID-19Further studiesCharacteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA 2021, 325: 1074-1087. PMID: 33625505, PMCID: PMC7905703, DOI: 10.1001/jama.2021.2091.Peer-Reviewed Original ResearchConceptsMultisystem inflammatory syndromeOrgan system involvementInflammatory syndromeCase seriesSystem involvementCardiorespiratory involvementCOVID-19Positive severe acute respiratory syndrome coronavirus 2Higher C-reactive protein levelsPositive RT-PCR test resultsSevere acute respiratory syndrome coronavirus 2Severe acute COVID-19Acute respiratory syndrome coronavirus 2C-reactive protein levelsSevere coronavirus disease 2019Left ventricular systolic functionRT-PCR test resultsRespiratory syndrome coronavirus 2Organ system complicationsAcute COVID-19Coronary artery aneurysmsVentricular systolic functionLow platelet countAntibody test resultsIntensive care unit